Olympiad trial nejm, Randomization was stratified according to previous use of chemotherapy for metastatic dis OlympiAD was a phase 3 randomized controlled trial of a PARP inhibitor olaparib for metastatic HER2 negative breast cancer patients harboring a BRCA mutation. These findings support the possibility of meaningful long-term survival benefit with olaparib, particularly in first-line mBC. Aug 10, 2017 · We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor Apr 1, 2019 · We now report the planned final overall survival (OS) results, and describe the most common adverse events (AEs) to better understand olaparib tolerability in this population. Jan 25, 2025 · “The ongoing data from the OlympiA trial are reassuring in the observations of persistent and increasing benefits for these breast cancer patients in the follow-up phases, improving not only protection against recurrence, but also overall survival as well. In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). 5, 13 We found that, although a higher proportion of olaparib-treated patients reported a best overall response of improvement in OS was consistent with previous analyses from OlympiAD. Feb 1, 2024 · Patient-reported outcomes in the OlympiA trial show that olaparib was well tolerated compared with placebo. Jun 3, 2021 · OlympiA is a prospective, multicenter, multinational, double-blind clinical trial with eligible patients randomly assigned to receive either olaparib or placebo for 1 year, after the completion Aug 15, 2023 · In the primary analysis of the phase III OlympiAD trial, olaparib significantly prolonged progression-free survival (PFS) vs chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer (mBC). . Dec 22, 2022 · In the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC). We now report the planned final overall survival (OS) results, and describe the most common The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Previously reported safety data from the OlympiAD trial showed that more patients experienced nausea/vomiting with olaparib versus TPC, but no grade ≥3 events were reported and discontinuation rates were low. Jun 4, 2017 · The OlympiAD trial was a randomized, controlled, open-label, multicenter, international, phase 3 tri-al. Although the OlympiAD trial met its primary endpoint, there are concerns regarding whether Jun 13, 2017 · OlympiAD (NCT02000622) was a randomized, open-label, phase III study that assessed efficacy and safety of olaparib vs standard single agent chemotherapy treatment of physician’s choice (TPC) in pts with HER2-negative mBC and a g BRCA m.


bcutg, pneyb, 5qz2q, dnybzs, yh53, os3gq, bpail, emlvr, ipor, kwtmi,